Alteon to Present at Bio Emerging Company Investor Forum Thursday, October 14, 2004

Alteon to Present at Bio Emerging Company Investor Forum
Thursday, October 14, 2004
- Presentation to be Webcast - 


PARSIPPANY, N.J., Oct. 7  /PRNewswire/ -- Alteon Inc. (AMEX:ALT) announced
today that it has been selected for a company presentation at the BIO Emerging
Company Investor Forum in San Francisco. Kenneth I. Moch, Alteon's President
and Chief Executive Officer, is scheduled to present at 3:00 p.m., Pacific
Time, on Thursday, October 14, 2004.

The live presentation will be webcast and will be accessible at the investor
relations section of Alteon's corporate website, http://www.alteon.com/, where
it also will be archived.

Note to Conference Attendees: Alteon has made time available for one-on-one
meetings. Please contact Susan Pietropaolo, , if you are interested in setting
up a meeting. Alternatively, you can request a meeting through the BIO
one-on-one meeting system.

About Alteon

Alteon is developing several new classes of drugs that reverse or slow down
diseases of aging and complications of diabetes. These compounds have an impact
on a fundamental pathological process caused by protein-glucose complexes
called Advanced Glycation End-products (A.G.E.s). The formation and
crosslinking of A.G.E.s lead to a loss of flexibility and function in body
tissues, organs and vessels and have been shown to be a causative factor in
many age-related diseases and diabetic complications. Alteon has created a
library of novel classes of compounds targeting the A.G.E. Pathway. Alteon's
lead compound alagebrium chloride (formerly ALT-711), the only A.G.E. Crosslink
Breaker in advanced human testing, has demonstrated safety and efficacy in
several Phase 2 trials and is actively being developed for systolic
hypertension and heart failure. Ongoing clinical trials include SPECTRA
(Systolic Pressure Efficacy and Safety Trial of Alagebrium) and PEDESTAL
(Patients with Impaired Ejection Fraction and Diastolic Dysfunction: Efficacy
and Safety Trial of ALagebrium), as well as a third trial exploring mechanism
of action in endothelial dysfunction.  For more information on Alteon, visit
the company's website at http://www.alteon.com/.

Any statements contained in this press release that relate to future plans,
events or performance are forward-looking statements that involve risks and
uncertainties including, but not limited to, those relating to technology and
product development (including the possibility that early clinical trial
results may not be predictive of results that will be obtained in large-scale
testing or that any clinical trials will not demonstrate sufficient safety and
efficacy to obtain requisite approvals or will not result in marketable
products), regulatory approval processes, intellectual property rights and
litigation, competitive products, ability to obtain financing, and other risks
identified in Alteon's filings with the Securities and Exchange Commission. The
information contained in this press release is accurate as of the date
indicated. Actual results, events or performance may differ materially. Alteon
undertakes no obligation to publicly release the result of any revision to
these forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. 

DATASOURCE: Alteon Inc.



CONTACT:  Susan M. Pietropaolo, Director, Corporate Communications &

Investor Relations, 



Web site:  http://www.alteonpharma.com/ 

Copyright